The AdVance Transobturator Male Sling for Postprostatectomy Incontinence: Clinical Results of a Prospective Evaluation after a Minimum Follow-up of 6 Months

Cornu, Jean‐Nicolas; Sèbe, Philippe; Ciofu, C.; Peyrat, L.; Beley, S.; Tligui, M.; Lukacs, B.; Traxer, Olivier; Cussenot, Olivier; Haab, F.

doi:10.1016/j.eururo.2009.09.015

Cited by 136 publications

(87 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have evaluated outcomes after AdVance implantation, and, currently, data up to a maximum follow-up of 39 months are available [12][13][14][15][16][17][18]. The AdVanceXP was marketed in 2010 and its innovations aim to improve both surgical implantation and postoperative stability.…”

Section: Discussionmentioning

confidence: 99%

Mid‐term outcomes after AdVanceXP male sling implantation

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo describe efficacy and safety of the AdVanceXP (Boston Scientific, Marlborough, MA, USA) retrourethral transobturator male sling after a mean follow‐up of almost 3 years.Patients and MethodsA total of 41 patients underwent AdVanceXP implantation between July 2010 and March 2012 by a single surgeon. Patients were prospectively evaluated at baseline, after a mean follow‐up of 12months and after an individual maximum follow‐up. Efficacy was evaluated by daily pad usage, 24‐h pad testing, and validated questionnaires (International Consultation on Incontinence questionnaire [ICIQ]). Patient satisfaction was determined using the Patient's Global Impression of Improvement score; quality of life was evaluated using the International Quality of Life (IQOL) score. Patients needing 0 or 1 safety pad with a daily urine loss <8 g were classified as cured. To assess the changes in outcome over time, a Wilcoxon signed‐rank test was used. A P value <0.05 was taken to indicate statistical significance.ResultsThe mean ± sd follow‐up was 33.1 ± 8.1 months. A total of four patients (9.8%) were lost to follow‐up. At follow‐up, 56.1% of patients used 0 or 1 dry safety pad, 17.1% used 1 pad, and 17.1% used 2 pads. Mean pad use was 0.6 pads per day (P < 0.001 vs baseline) with a mean urine loss of 14 g per day. After nearly 3 years, 46.3% of the patients could be classified as cured and 29.3% could be classified as improved. When comparing respective outcomes after 1 and 3 years, no significant changes in mean daily pad use (0.8 at 1 year; P = 1.000), in ICIQ score (5.0 at 3 years vs 5.2 at 1 year; P = 0.500), or in IQOL score (89.2 at 3 years vs 86.8 at 1 year; P = 0.500) were observed. Patients lost less urine based on 24‐h pad testing after nearly 3 years (14 g at 3 years vs 28 g at 1 year; P = 0.106). Subgroup analyses showed no significant differences in efficacy in patients who had previously received radiotherapy or in patients with mild preoperative incontinence. Between 1 and 3 years postoperatively, no complications were detected.ConclusionsThe present study had the longest follow‐up for AdVanceXP to date and is the first to show a high efficacy even after a mean follow‐up of almost 3 years. The results indicate that late‐onset complications are rare after AdVanceXP implantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Mid‐term outcomes after AdVanceXP male sling implantation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Synthetic slings have been shown to have better results than other materials (e.g., biologic), and surgical approaches continue to expand [ 220 ] . In 2007, a transobturator approach was reported, and recent studies indicate moderate success rates (Advance) [ 185,195,196,[221][222][223][224] . This approach is thought to enable functional lumen occlusion rather than the pure urethral compression from the arti fi cial urinary sphincter [ 9 ] .…”

Section: Urethral Slingsmentioning

confidence: 95%

“…Cure rates range from 37 to 65 % with success/improvement rates even higher depending on the de fi nition [ 193,196,228 ] . Outcomes for continence/cure are typically de fi ned as no pad or one dry pad/day with improvements de fi ned in some studies as a decrease in pad use by 50 % [ 196,221 ] .…”

Section: Urethral Slingsmentioning

confidence: 98%

See 1 more Smart Citation

Urinary Incontinence

Skolarus

2012

Prostate Cancer: A Comprehensive Perspective

View full text Add to dashboard Cite

“…In einer multizentrischen Untersuchung konnte außerdem gezeigt werden, dass die Ergebnisse auch 3 Jahre postoperativ stabil bleiben und nach den ersten 12 Monaten keine weiteren Komplikationen auftreten [34,36,37,38,39]. Bei Patienten mit zusätzlicher Radiotherapie zeigt die AdVance™-Schlinge deutlich reduzierte Erfolgsraten [37,40]. Die Hauptkomplikationen umfassen passagere postoperative Harnverhaltung mit vorübergehen-der Notwendigkeit zur Katheterisierung (≤21%), lokale Wundinfektionen, fieberhafte Harnwegsinfektion sowie perineale Beschwerden.…”

Section: Retrourethrale Transobturatorische Schlinge -Funktionelle Scunclassified

Urinary incontinence in men

Bauer

Oelke

Hübner

et al. 2015

Urologe

View full text Add to dashboard Cite

Stress urinary incontinence in men is predominantly iatrogenic whereby radical prostatectomy is the most common cause with persistent stress urinary incontinence rates varying between 10 % and 25 %. The first line therapy for postoperative male stress urinary incontinence is physiotherapy, especially pelvic floor muscle rehabilitation. If conservative treatment fails to show sufficient improvement, surgical therapy is recommended. Several treatment options are currently available for the surgical treatment of male stress urinary incontinence including artificial sphincters, adjustable and functional sling systems, bulking agents and implantable balloon systems.

show abstract

The AdVance Transobturator Male Sling for Postprostatectomy Incontinence: Clinical Results of a Prospective Evaluation after a Minimum Follow-up of 6 Months

Cited by 136 publications

References 26 publications

Mid‐term outcomes after AdVanceXP male sling implantation

Mid‐term outcomes after AdVanceXP male sling implantation

Urinary Incontinence

Urinary incontinence in men

Contact Info

Product

Resources

About